Oppenheimer Downgrades Sensei Biotherapeutics to Perform
Oppenheimer analyst Kevin DeGeeter downgrades Sensei Biotherapeutics (NASDAQ:SNSE) from Outperform to Perform.
Piper Sandler Downgrades Carvana to Neutral, Raises Price Target to $306
Piper Sandler downgrades Carvana (NYSE:CVNA) from Overweight to Neutral and raises the price target from $303 to $306.
Keybanc Downgrades Berkeley Lights to Sector Weight
Keybanc analyst Paul Knight downgrades Berkeley Lights (NASDAQ:BLI) from Overweight to Sector Weight.
Alembic Global Downgrades Virgin Galactic Hldgs to Neutral
Alembic Global analyst Peter Skibitski downgrades Virgin Galactic Hldgs (NYSE:SPCE) from Overweight to Neutral.
William Blair Downgrades QAD to Market Perform
William Blair analyst Bhavan Suri downgrades QAD (NASDAQ:QADA) from Outperform to Market Perform.
RBC Capital Downgrades Sandstorm Gold to Underperform, Lowers Price Target to $7
RBC Capital analyst Josh Wolfson downgrades Sandstorm Gold (NYSE:SAND) from Sector Perform to Underperform and lowers the price target from $8 to $7.
Raymond James Downgrades Maximus to Outperform, Lowers Price Target to $105
Raymond James analyst Brian Gesuale downgrades Maximus (NYSE:MMS) from Strong Buy to Outperform and lowers the price target from $110 to $105.
JP Morgan Downgrades Global Blood Therapeutics to Neutral, Announces $36 Price Target
JP Morgan analyst Tessa Romero downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and announces $36 price target.
Goldman Sachs Downgrades BRF to Neutral, Announces $6.1 Price Target
Goldman Sachs analyst Thiago Bortoluci downgrades BRF (NYSE:BRFS) from Buy to Neutral and announces $6.1 price target.
Why This Analyst Sees Downside to New Jersey Resources’ Valuation
New Jersey Resources Corporation (NYSE: NJR), an energy services company, will likely face two challenges, according to an analyst at BofA Securities.